中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 8
Aug.  2023
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2023  >  39(8): 1972-1976

Research advances in local treatment combined with systemic therapy for advanced hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2023.08.031

  • Department of Hepatology, Nanjing Hospital Affiliated to Nanjing University of Chinese Medicine & Nanjing Second Hospital, Nanjing 210003, China

Research funding:

Key Program of Jiangsu Commision of Health (ZD2021061)

More Information
  • Corresponding author: YANG Yongfeng, yyf1979@163.com (ORCID: 0000-0002-0942-4833)
  • Received Date: 2022-11-08
  • Accepted Date: 2022-12-12
  • Published Date: 2023-08-20
    Abstract
  • Most patients with hepatocellular carcinoma (HCC) have reached the advanced stage at the time of diagnosis in China, and a single treatment regimen tends to have a low objective response rate (ORR), while combined therapy can significantly increase the ORR of patients with advanced HCC and prolong their survival time. The article elaborates on the latest research advances in the efficacy of local treatment combined with systemic therapy for advanced HCC.

     

    • FullText(HTML)
  • loading
    • References(35)
  • [1]
    JEMAL A, WARD EM, JOHNSON CJ, et al. Annual report to the nation on the status of cancer, 1975-2014, featuring survival[J]. J Natl Cancer Inst, 2017, 109(9): djx030. DOI: 10.1093/jnci/djx030.
    [2]
    KUANG M. Advances in neoadjuvant therapy for hepatocellular carcinoma[J]. Chin J Dig Surg, 2023, 22(2): 202-208. DOI: 10.3760/cma.j.cn115610-20221203-00728.

    匡铭. 肝细胞癌新辅助治疗研究进展[J]. 中华消化外科杂志, 2023, 22(2): 202-208. DOI: 10.3760/cma.j.cn115610-20221203-00728.
    [3]
    LIU YY. New progress of hepatocellular carcinoma treatment[J]. Chin J Dig Surg, 2022, 21(1): 15-18. DOI: 10.3760/cma.j.cn115610-20220107-00020.

    刘允怡. 肝细胞癌治疗的新发展[J]. 中华消化外科杂志, 2022, 21(1): 15-18. DOI: 10.3760/cma.j.cn115610-20220107-00020.
    [4]
    XUE J, NI H, WANG F, et al. Advances in locoregional therapy for hepatocellular carcinoma combined with immunotherapy and targeted therapy[J]. J Interv Med, 2021, 4(3): 105-113. DOI: 10.1016/j.jimed.2021.05.002.
    [5]
    KUDO M, UESHIMA K, IKEDA M, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial[J]. Gut, 2020, 69(8): 1492-1501. DOI: 10.1136/gutjnl-2019-318934.
    [6]
    LIU J, XU J, ZHANG W, et al. Safety and efficacy of drug-eluting bead transarterial chemoembolization combined with apatinib in patients with advanced hepatocellular carcinoma[J]. Acad Radiol, 2020, 27(5): 704-709. DOI: 10.1016/j.acra.2019.07.003.
    [7]
    PINTER M, ULBRICH G, SIEGHART W, et al. Hepatocellular carcinoma: A phase ii randomized controlled double-blind trial of transarterial chemoembolization in combination with biweekly intravenous administration of bevacizumab or a placebo[J]. Radiology, 2015, 277(3): 903-912. DOI: 10.1148/radiol.2015142140.
    [8]
    ZHANG H, CAO G, REN W, et al. Vascular normalization therapy with targeted localized vessel bevacizumab infusion in hepatocellular carcinoma after transarterial chemoembolization failure[J]. Ann Palliat Med, 2021, 10(8): 9149-9156. DOI: 10.21037/apm-21-2123.
    [9]
    MARINELLI B, KIM E, D'ALESSIO A, et al. Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study[J]. J Immunother Cancer, 2022, 10(6): e004205. DOI: 10.1136/jitc-2021-004205.
    [10]
    MARINELLI B, KIM E, D'ALESSIO A, et al. Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study[J]. J Immunother Cancer, 2022, 10(6): e004205. DOI: 10.1136/jitc-2021-004205.
    [11]
    PFISTER D, NÚÑEZ NG, PINYOL R, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC[J]. Nature, 2021, 592(7854): 450-456. DOI: 10.1038/s41586-021-03362-0.
    [12]
    XIANG YJ, WANG K, YU HM, et al. Transarterial chemoembolization plus a PD-1 inhibitor with or without lenvatinib for intermediate-stage hepatocellular carcinoma[J]. Hepatol Res, 2022, 52(8): 721-729. DOI: 10.1111/hepr.13773.
    [13]
    CAO F, YANG Y, SI T, et al. The efficacy of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a multicenter retrospective study[J]. Front Oncol, 2021, 11: 783480. DOI: 10.3389/fonc.2021.783480.
    [14]
    LI X, FU Z, CHEN X, et al. Efficacy and safety of lenvatinib combined with PD-1 inhibitors plus tace for unresectable hepatocellular carcinoma patients in china real-world[J]. Front Oncol, 2022, 12: 950266. DOI: 10.3389/fonc.2022.950266.
    [15]
    LLOVET JM, VOGEL A, MADOFF DC, et al. Randomized phase 3 LEAP-012 study: transarterial chemoembolization with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma not amenable to curative treatment[J]. Cardiovasc Intervent Radiol, 2022, 45(4): 405-412. DOI: 10.1007/s00270-021-03031-9.
    [16]
    CHOI JH, CHUNG WJ, BAE SH, et al. Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis[J]. Cancer Chemother Pharmacol, 2018, 82(3): 469-478. DOI: 10.1007/s00280-018-3638-0.
    [17]
    HE M, LI Q, ZOU R, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial[J]. JAMA Oncol, 2019, 5(7): 953-960. DOI: 10.1001/jamaoncol.2019.0250.
    [18]
    YAMAMOTO S, ONISHI H, TAKAKI A, et al. The early decline of α-fetoprotein and des-γ-carboxy prothrombin predicts the response of hepatic arterial infusion chemotherapy in hepatocellular carcinoma patients[J]. Gastrointest Tumors, 2020, 7(3): 83-92. DOI: 10.1159/000506941.
    [19]
    MEI J, LI SH, LI QJ, et al. Anti-PD-1 immunotherapy improves the efficacy of hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma[J]. J Hepatocell Carcinoma, 2021, 8: 167-176. DOI: 10.2147/JHC.S298538.
    [20]
    YI X, FU Y, LONG Q, et al. Myosteatosis can predict unfavorable outcomes in advanced hepatocellular carcinoma patients treated with hepatic artery infusion chemotherapy and Anti-PD-1 immunotherapy[J]. Front Oncol, 2022, 12: 892192. DOI: 10.3389/fonc.2022.892192.
    [21]
    LIU BJ, GAO S, ZHU X, et al. Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma[J]. Immunotherapy, 2021, 13(17): 1395-1405. DOI: 10.2217/imt-2021-0192.
    [22]
    CHEN S, XU B, WU Z, et al. Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study[J]. BMC Cancer, 2021, 21(1): 1126. DOI: 10.1186/s12885-021-08858-6.
    [23]
    MEHTA A, OKLU R, SHETH RA. Thermal ablative therapies and immune checkpoint modulation: can locoregional approaches effect a systemic response?[J]. Gastroenterol Res Pract, 2016, 2016: 9251375. DOI: 10.1155/2016/9251375.
    [24]
    KAN X, JING Y, WAN QY, et al. Sorafenib combined with percutaneous radiofrequency ablation for the treatment of medium-sized hepatocellular carcinoma[J]. Eur Rev Med Pharmacol Sci, 2015, 19(2): 247-255.
    [25]
    BRUIX J, TAKAYAMA T, MAZZAFERRO V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2015, 16(13): 1344-1354. DOI: 10.1016/S1470-2045(15)00198-9.
    [26]
    DUFFY AG, ULAHANNAN SV, MAKOROVA-RUSHER O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma[J]. J Hepatol, 2017, 66(3): 545-551. DOI: 10.1016/j.jhep.2016.10.029.
    [27]
    WANG X, LIU G, CHEN S, et al. Combination therapy with PD-1 blockade and radiofrequency ablation for recurrent hepatocellular carcinoma: a propensity score matching analysis[J]. Int J Hyperthermia, 2021, 38(1): 1519-1528. DOI: 10.1080/02656736.2021.1991011.
    [28]
    LIU CM, HUANG BS, YEN YH, et al. Concurrent sorafenib and radiotherapy versus radiotherapy alone for locally advanced hepatocellular carcinoma: a propensity-matched analysis[J]. J Hepatocell Carcinoma, 2021, 8: 963-973. DOI: 10.2147/JHC.S323302.
    [29]
    FACCIORUSSO A, PAOLILLO R, TARTAGLIA N, et al. Efficacy of combined transarterial radioembolization and sorafenib in the treatment of hepatocarcinoma: A meta-analysis[J]. Dig Liver Dis, 2022, 54(3): 316-323. DOI: 10.1016/j.dld.2021.06.003.
    [30]
    ABULIMITI M, LI Z, WANG H, et al. Combination intensity-modulated radiotherapy and sorafenib improves outcomes in hepatocellular carcinoma with portal vein tumor thrombosis[J]. J Oncol, 2021, 2021: 9943683. DOI: 10.1155/2021/9943683.
    [31]
    EDELINE J, CROUZET L, CAMPILLO-GIMENEZ B, et al. Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis[J]. Eur J Nucl Med Mol Imaging, 2016, 43(4): 635-643. DOI: 10.1007/s00259-015-3210-7.
    [32]
    QASEEM Y, SALEM R. Observing durable responses and a prolonged survival tail in advanced hepatocellular carcinoma with portal vein invasion treated with Y90 radioembolization[J]. Cardiovasc Intervent Radiol, 2020, 43(9): 1423-1424. DOI: 10.1007/s00270-020-02541-2.
    [33]
    CHIANG CL, CHAN A, CHIU K, et al. Combined stereotactic body radiotherapy and checkpoint inhibition in unresectable hepatocellular carcinoma: a potential synergistic treatment strategy[J]. Front Oncol, 2019, 9: 1157. DOI: 10.3389/fonc.2019.01157.
    [34]
    ZHAN C, RUOHONIEMI D, SHANBHOGUE KP, et al. Safety of combined yttrium-90 radioembolization and immune checkpoint inhibitor immunotherapy for hepatocellular carcinoma[J]. J Vasc Interv Radiol, 2020, 31(1): 25-34. DOI: 10.1016/j.jvir.2019.05.023.
    [35]
    TAI D, LOKE K, GOGNA A, et al. Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2021, 6(12): 1025-1035. DOI: 10.1016/S2468-1253(21)00305-8.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (329) PDF downloads(99) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return